Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib

European Journal of Cancer

Volumn 43, Issue 1, 2007, Pages 55-63

  Mross, K ^a   Steinbild, S ^a   Baas, F ^a   Gmehling, D ^a   Radtke, M ^b   Voliotis, D ^b   Brendel, E ^b   Christensen, O ^b   Unger, C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Irinotecan; Multi kinase inhibitor; Phase I; Sorafenib

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CYTOTOXIC AGENT; DRUG METABOLITE; FLUOROURACIL; HEMOGLOBIN; IRINOTECAN; OXALIPLATIN; PHOSPHOTRANSFERASE INHIBITOR; SORAFENIB; TRIACYLGLYCEROL LIPASE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG GLUCURONIDATION; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; GRANULOCYTE; HAND FOOT SYNDROME; HUMAN; IN VITRO STUDY; INFECTION; LEUKOCYTE; LIVER METASTASIS; LIVER MICROSOME; MALE; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL COUNT; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SKIN MANIFESTATION; SOLID TUMOR; STOMATITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CAMPTOTHECIN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; NEOPLASMS; PYRIDINES; TREATMENT OUTCOME;

EID: 33846020023     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.08.032     Document Type: Article

References (33)

1. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
2. Wilhelm S., and Chien D.S. BAY 43-9006: preclinical data. Current Pharmaceutical Design 8 (2002) 2255-2257
3. Ostman A., and Heldin C.H. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res 80 (2001) 1-38
4. Lima J., Trovisco V., Soares P., et al. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 89 (2004) 4267-4271
5. Salvatore G., Giannini R., Faviana P., et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 89 (2004) 5175-5180
6. Kolch W., Kotwaliwale A., Vass K., and Janosch P. The role of Raf kinases in malignant transformation. Expert Rev Mol Med 2002 (2002) 1-18
7. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3 (2003) 11-22
8. Strumberg D., Richly H., Hilger R.A., et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 (2005) 965-972
9. Moore M., Hirte H.W., Siu L., et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16 (2005) 1688-1694
10. Clark J.W., Eder J.P., Ryan D., Lee R., and Lenz H.-J. The safety and pharmacokinetics of the multi-targeted tyrosine kinase inhibitor (including Raf kinase and VEGF kinase), BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11 (2005) 5472-5480
11. Awada A., Hendlisz A., Gil T., et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92 (2005) 1855-1861
12. Escudier B., Szczylik C., Eisen T., et al. Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer Suppl 3 (2005) 226 (abstract 794 and oral presentation)
13. Ratain M.J., Eisen T., Stadler W.M., et al. Final findings from a Phase II, placebo controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 23 (2005) 388s
14. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of BAY 43-9006 in patients with advanced hepatocellular carcinoma (HCC). Eur J Cancer 2 (2004) 16 Abstract 42
15. Glimelius B. Benefit-risk assessment of irinotecan in advanced colorectal cancer. Drug Saf 28 (2005) 417-433
16. Heim M., Sharifi M., Hilger R.A., Scheulen M.E., Seeber S., and Strumberg D. Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006. Int J Clin Pharmacol Ther 41 (2003) 616-617
17. Vincent R., Bernando V., Chen C., Zhang X., and Carter C. Chemotherapy with BAY 43-9006 in combination with Irinotecan or administered as repeated cycles of therapy against the DLD-1 human tumor xenograft. Clin Cancer Res (2003) 44 Abstract 4469
18. Haaz M.C., Rivory L., Riche C., Vernillet L., and Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 58 (1998) 468-472
19. Lathia C., Lettieri J., Cihon F., Gallentine M., Radtke M., and Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 57 (2006) 685-692
20. Radtke M., Schmeer K., Hafner F.T., Brendel E., and Lathia C. Oxidative metabolism of sorafenib. Drug Metab Rev 37 (2005) 67
21. Iyer L., King C.D., Whitington P.F., et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101 (1998) 847-854
22. Gagne J.F., Montminy V., Belanger P., Journault K., Gaucher G., and Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62 (2002) 608-617
23. Hanioka N., Ozawa S., Jinno H., Ando M., Saito Y., and Sawada J. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 31 (2001) 687-699
24. Villeneuve L., Girard H., Fortier L.C., Gagne J.F., and Guillemette C. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 307 (2003) 117-128
25. Socinski M.A., Sandler A.B., Miller L.L., et al. Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial. Clin Lung Cancer 2 Suppl 2 (2001) S26-S33
26. Mathijssen R.H., Verweij J., de Jonge M.J., Nooter K., Stoter G., and Sparreboom A. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 20 (2002) 81-87
27. Vincent P, Zhang X, Chen C, et al. Preclinical chemotherapy with the Raf kinase inhibitor BAY 43-9006 in combination with gefitinib, vinorelbine, gemcitabine or doxorubicin. Clin Cancer Res 2003;44(2nd ed):Abstract 719.
28. Siu L.L., Awada A., Takimoto C.H., et al. A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer. Proc Am Soc Clin Oncol 23 (2004) 209 Abstract 3059
29. Richly H., Kupsch P., Passage K., et al. Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with refractory solid tumors. J Clin Oncol 23 (2004) 207 Abstract 3049
30. Flaherty K.T., Brose M., Schuchter L., et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol 22 (2004) 7507 Abstract
31. Flaherty K.T., Lee R.J., Humphries R., O'Dwyer P.J., and Schiller J. Phase I trial of BAY 43-9006 in combination with carboplatin (C) and paclitaxel (P). Proc Am Soc Clin Oncol 22 (2003) 710
32. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
33. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004) 229-237